本帖最后由 老马 于 2012-1-13 21:20 编辑 ) k0 j' C- k4 j# J7 ^2 Z
7 v4 ]0 P& C3 I' }2 e, C2 j d4 A/ g5 }
爱必妥和阿瓦斯丁的比较
# J' w: ~0 r# _" O* G
5 g* D% O) g/ ~9 E4 Nhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/- m- x0 W: R4 n0 l
( ?5 N/ ^% h& ^8 R: ]$ F/ P
5 t+ C3 @: [) N zhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( h! i) ~! F6 e5 f. I6 w3 U. s& H
==================================================- I# T2 G' g( Q
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) |2 E3 C" T, K) A$ C1 n( w4 [Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ b9 W' j* W: } T+ DResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
# N4 u8 R. E4 z# h1 F
|